enow.com Web Search

  1. Ad

    related to: secondary erythrocytosis treatment list of medications drugs approved by insurance

Search results

  1. Results from the WOW.Com Content Network
  2. Sunitinib - Wikipedia

    en.wikipedia.org/wiki/Sunitinib

    Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer ...

  3. Erythropoiesis-stimulating agent - Wikipedia

    en.wikipedia.org/wiki/Erythropoiesis-stimulating...

    The 2020 Cochrane Anaesthesia Review Group review of erythropoietin (EPO) plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non‐cardiac surgery [11] demonstrated that patients were much less likely to require red cell transfusion and in those transfused, the volumes were unchanged (mean ...

  4. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with locally advanced or metastatic non- small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Osimertinib: Treatment of adults with locally advanced, unresectable ...

  5. List of chemotherapeutic agents - Wikipedia

    en.wikipedia.org/wiki/List_of_chemotherapeutic...

    This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision. Each drug is listed once (at present), though it might fall in more than one subsection. A full alphabetical listing is included after the categorical listing.

  6. List of selective estrogen receptor modulators - Wikipedia

    en.wikipedia.org/wiki/List_of_selective_estrogen...

    SERMs that have not been approved for medical use include arzoxifene, brilanestrant, clomifenoxide (clomiphene N-oxide; metabolite of clomifene), [3] droloxifene (3-hydroxytamoxifen), etacstil, fispemifene, GW-7604 (4-hydroxyetacstil; metabolite of etacstil), idoxifene (pyrrolidino-4-iodotamoxifen), levormeloxifene ((L)-ormeloxifene), miproxifene, nafoxidine, nitromifene (CI-628), NNC 45-0095 ...

  7. ‘No one should have to be fighting cancer and insurance at ...

    www.aol.com/no-one-fighting-cancer-insurance...

    Diagnosed with leukemia three years ago, Tsoukalas, 26, was stunned to learn that her insurer’s coverage of the drug she needed came with a $13,000 monthly copay, which the recent college ...

  8. Lumacaftor/ivacaftor - Wikipedia

    en.wikipedia.org/wiki/Lumacaftor/ivacaftor

    On 25 October, the Dutch Minister of Health announced that an agreement had been brokered with Vertex Pharmaceuticals, the company that manufactures the drug, resulting in admittance to the Dutch public health insurance package. Part of the agreement is that the result of the negotiation about the price of the treatment will not be disclosed.

  9. Belimumab - Wikipedia

    en.wikipedia.org/wiki/Belimumab

    When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]

  1. Ad

    related to: secondary erythrocytosis treatment list of medications drugs approved by insurance
  1. Related searches secondary erythrocytosis treatment list of medications drugs approved by insurance

    erythropoiesis stimulant drugserythropoiesis stimulating agent